Neko Health raises $700 million to take preventive scans to the US
The Spotify co-founder’s health-scan company has now raised two large rounds in 2025, but did not disclose valuation, revenue or headcount.
By Marcus Adeyemi · Startups Editor
· 3 min read
Neko Health has raised a $700 million Series C led by Lightspeed Venture Partners and co-led by O.G. Venture Partners to expand its preventive health-scan clinics into the US. The deal is a large follow-on to its $260 million Series B in January 2025 and signals continued investor appetite for consumer health services that package diagnostics, software and clinic operations into a single visit.
The company did not disclose its valuation, revenue, profitability or headcount. Existing investors Atomico, General Catalyst and Lakestar also participated, along with new backers Liberty City Ventures, Positive Sum and BDT & MSD.
Founded by Spotify co-founder Daniel Ek and Hjalmar Nilsonne, Neko Health sells a 60-minute scan that combines sensor-based imaging with blood analysis. The scan costs £299 in the UK and 2,750 SEK in Sweden. Neko says the appointment checks skin health, including moles and marks, and looks at biomarkers tied to pre-diabetes risk, blood abnormalities, metabolic syndrome, stroke and heart attack risk factors.
Results are provided at the clinic shortly after the scan and reviewed in person with a medical professional, according to the company. Neko’s pitch is that it can move parts of preventive care into a faster, repeatable consumer service. The harder question, which the company is trying to answer with follow-up data, is whether the model produces measurable health gains beyond high customer demand.
Expansion follows clinic and hardware upgrades
Neko said the new capital will support its first move into the US, while also funding research and product development. Nilsonne, the company’s co-founder and CEO, said the round would help take the company’s prevention model to the US and continue investment in the technology behind it. He also said most members return after their first scan and that repeat members show improving health markers.
The company recently added body composition measurements to the scan and clinician review of wearable-device data across its clinics. Neko said the body composition data is captured in seconds during the appointment, while wearable review is intended to give clinicians information from the period between visits.
Last month, Neko opened another Stockholm clinic using new versions of its own medical devices: Derma-2, Echo-2 and Spectrum-2. The company says the devices collect more and higher-quality signals across skin, heart and circulation, and use more automation so clinical staff can spend more time with members. Neko said it plans to deploy the upgraded hardware across its clinics in the next few months.
Demand data is strong, outcomes data is still company-reported
Since its February 2023 launch, Neko has opened clinics in Sweden and the UK, including Manchester, Birmingham and several London sites: Marylebone, Spitalfields, Covent Garden and Victoria. The company says more than 350,000 people have registered for a scan and more than 100,000 members have completed one.
Neko also says 75% of members, on average, book and pay for the following year’s scan at the end of their appointment. That is the most concrete demand signal the company disclosed, though it did not break out utilization by clinic, revenue per site or waitlist conversion.
The company reported that, among returning members with previously identified severe or life-threatening conditions, three in four were later in good health or had their conditions under control. It also said five of seven key biomarkers improved by a statistically significant amount between a first and second scan. Neko did not provide the underlying sample size, study design or baseline figures in the announcement.
Lightspeed global partner Bejul Somaia said the firm backed Neko because of its growth, technology and consumer demand. Tim Ferriss, an author and investor in the round, said he invested because the service combines several health-tracking steps into one appointment at a lower price point than the fragmented alternatives he has used.
As part of the financing, David Ofer of O.G. Venture Partners is expected to join Neko Health’s board, pending regulatory approval.
This story draws on original reporting from Tech.eu.
